Clinical and laboratory indicators for infectious mononucleosis in children on the background of the treatment with valavir

Authors

  • Ya. V. Kolesnik Kharkiv National Medical University, Ukraine

DOI:

https://doi.org/10.24959/cphj.18.1442

Keywords:

infectious mononucleosis, acyclic nucleoside analogs, treatment, clinical indicators

Abstract

Infectious mononucleosis (IM) is an acute infectious disease accompanied with fever, quinsy, damage of lymph nodes, liver, spleen and characteristic changes in the hemogram. The global spread of IM among the population, frequency of its chronic course, the presence of erased and atypical forms, the complexity of diagnosis and therapy cause the urgency of the problem of studying IM.
Aim. To compare clinical and laboratory indicators in the acute period of IM in children treated with valavir.                                                                          Materials and methods. The article contains the results of the own observations of 107 children with IM aged 2 to 15 years. Clinical and laboratory data were evaluated in patients with IM on the background of the treatment with valavir. Results. The main therapy was antihistamines and symptomatic drugs, antimicrobials were prescribed for the treatment of quinsy. Valavir was prescribed on the first day of admission with clinical verification of the diagnosis. Verification of pathogens was carried out by the method of enzyme immunoassay, specific immunoglobulins M and G were determined separately for VEB antigens by the PCR method. The disease in all children was accompanied with fever, tonsillitis, lymphadenopathy, enlargement of the liver and spleen. The study of clinical and laboratory features was conducted at the time of admission to the hospital and on the 12th day of hospitalization.        Conclusions. According to the results of the study the conclusions have been made that prescription of valavir in the treatment of acute infectious mononucleosis in children leads to a more rapid disappearance of a number of clinical symptoms and normalization of laboratory indicators compared to patients who received only the symptomatic and pathogenetic therapy.

References

Gorokhova, L. A., Saraeva, N. O. (2000). Sibirskii meditcinskii zhurnal, 3, 14–17.

Tiuniaeva, N. O., Sofronova L. V. (2014). Vestnik novykh meditcinskikh tekhnologii – Journal of New Medical Technologies, 3, 184–190.

Kazmirchuk, V. E., Maltcev, D. V. (2011). Klinicheskaia immunologiia. Allergologiia. Infektologiia, 5 (91), 69–75.

Kramarev, S. A., Vygovskaia, O. V. (2013). Aktualnaia infektologiia – Actual Infectology, 1 (1), 73–78.

Vygovskaia, O. V., Kramarev, S. A., Doroshenko, V. O., Shpak, I. V. (2012). Praktykuiuchyi likar, 4, 29–34.

Downloads

Published

2018-03-14

Issue

Vol. 22 No. 1 (2018)

Section

Clinical Pharmacology and Pharmacotherapy

License

Copyright (c) 2018 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).